SAN FRANCISCO (MarketWatch) -- Barr Pharmaceuticals Inc. said Wednesday a federal appeals court has affirmed a February 2005 lower court decision that granted summary judgment in favor of its Barr ...
Intranasal desmopressin (DDAVP, DDVP, Minirin, Stimate Nasal Spray) is no longer indicated for primary nocturnal enuresis and is associated with an increased risk of severe hyponatremia (possibly ...
ROCKVILLE, Md., Dec.4, 2007-- FDA notified healthcare professionals and patients of the Agency's request that manufacturers update the prescribing information for desmopressin to include important new ...
Nocturia is fairly prevalent. A review by Bosch and Weiss [3] noted that most older men and women experience at least 1 void per night and on average two thirds of patients experience 2 or more voids ...
The FDA has assigned a Prescription Drug User Fee Act target date of February 25, 2026 to the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ET-600 ...
In a study, users of the older formulation of desmopressin had a 13-fold higher rate of hyponatremia than users of oxybutynin. Use of an older formulation of desmopressin, which is sometimes ...
The batch was distributed between August 14, 2018 and September 5, 2018. One nonfatal adverse event has been reported during the timeframe the affected product was distributed. Ferring has announced a ...
(CN) - The 2nd Circuit has reinstated an antitrust class action accusing drug makers Ferring and Aventis of hiking prices on the diabetes drug desmopressin acetate, known as DDAVP. The Manhattan court ...
Background and aims: Nocturnal enuresis is psychosocially detrimental to children affected by it. First-line treatment involves offering emotional support and promoting appropriate voiding patterns.
Ferring Pharmaceuticals US is voluntarily recalling all lots on the market of DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE® Nasal Spray 1.5 mg/mL listed ...
Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Two phase 3 placebo-controlled randomized trials show the formulation significantly prolongs the first uninterrupted sleep period and proportion of nights with 1 or fewer nocturic episodes. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback